TrialNature communications2024

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.

Jingyun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.